Biologic therapy in relapsing polychondritis: navigating between options

References

• Puéchal X, Terrier B, Mouthon L, et al. Relapsing polychondritis. Joint Bone Spine. 2014;81(2):118–124.
   PubMed Web of Science ®Google Scholar
• Mathian A, Miyara M, Cohen-Aubart F, et al. Relapsing polychondritis: a 2016 update on clinical features, diagnostic tools, treatment and biological drug use. Best Pract Res Clin Rheumatol. 2016;30(2):316–333.
   PubMed Web of Science ®Google Scholar
• Alqanatish JT, Alshanwani JR. Relapsing polychondritis in children: a review. Mod Rheumatol. 2020;30(5):788–798.
   PubMed Web of Science ®Google Scholar
• Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med. 1998;129(2):114–122.
   PubMed Web of Science ®Google Scholar
• Horváth A, Páll N, Molnár K, et al. A nationwide study of the epidemiology of relapsing polychondritis. Clin Epidemiol. 2016;8:211–230.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Mathian A, Haroche J, et al. Pathogenesis of relapsing polychondritis: a 2013 update. Autoimmun Rev. 2014;13(2):90–95.
   PubMed Web of Science ®Google Scholar
• Zeuner M, Straub RH, Rauh G, et al. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol. 1997;24(1):96–101.
   PubMed Web of Science ®Google Scholar
• Hansson AS, Heinegård D, Piette JC, et al. The occurrence of autoantibodies to matrilin 1 reflects a tissue-specific response to cartilage of the respiratory tract in patients with relapsing polychondritis. Arthritis Rheum. 2001;44(10):2402–2412.
   PubMed Web of Science ®Google Scholar
• Kempta Lekpa F, Piette JC, Bastuji-Garin S, et al. Serum cartilage oligomeric matrix protein (COMP) level is a marker of disease activity in relapsing polychondritis. Clin Exp Rheumatol. 2010;28(4):553–555.
   PubMed Web of Science ®Google Scholar
• Ebringer R, Rook G, Swana GT, et al. Autoantibodies to cartilage and type II collagen in relapsing polychondritis and other rheumatic diseases. Ann Rheum Dis. 1981;40(5):473–479.
   PubMed Web of Science ®Google Scholar
• Buckner JH, Van Landeghen M, Kwok WW, et al. Identification of type II collagen peptide 261-273-specific T cell clones in a patient with relapsing polychondritis. Arthritis Rheum. 2002;46(1):238–244.
   PubMedGoogle Scholar
• Stabler T, Piette JC, Chevalier X, et al. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum. 2004;50(11):3663–3667.
   PubMed Web of Science ®Google Scholar
• Dion J, Costedoat-Chalumeau N, Sène D, et al. Relapsing polychondritis can be characterized by three different clinical phenotypes: analysis of a recent series of 142 patients. Arthritis Rheumatol. 2016;68(12):2992–3001. (Hoboken, NJ).
   PubMed Web of Science ®Google Scholar
• McAdam LP, O’Hanlan MA, Bluestone R, et al. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore). 1976;55(3):193–215. (Baltimore).
   PubMed Web of Science ®Google Scholar
• Damiani JM, Levine HL. Relapsing polychondritis–report of ten cases. Laryngoscope. 1979;89(6 Pt 1):929–946.
   PubMed Web of Science ®Google Scholar
• Michet CJ, McKenna CH, Luthra HS, et al. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med. 1986;104(1):74–78.
   PubMed Web of Science ®Google Scholar
• Sato T, Yamano Y, Tomaru U, et al. Serum level of soluble triggering receptor expressed on myeloid cells-1 as a biomarker of disease activity in relapsing polychondritis. Mod Rheumatol. 2014;24(1):129–136.
   PubMed Web of Science ®Google Scholar
• Terato K, Shimozuru Y, Katayama K, et al. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum. 1990;33(10):1493–1500.
   PubMedGoogle Scholar
• Yamashita H, Takahashi H, Kubota K, et al. Utility of fluorodeoxyglucose positron emission tomography/computed tomography for early diagnosis and evaluation of disease activity of relapsing polychondritis: a case series and literature review. Rheumatology. 2014;53(8):1482–1490. (Oxford).
   PubMed Web of Science ®Google Scholar
• Hazra N, Dregan A, Charlton J, et al. Incidence and mortality of relapsing polychondritis in the UK: a population-based cohort study. Rheumatology. 2015;54(12):2181–2187. (Oxford).
   PubMed Web of Science ®Google Scholar
• Borgia F, Giuffrida F, and Guarneri F, et al. Relapsing polychondritis: an updated review. Biomedicines. 2018;6(3):84.
   Web of Science ®Google Scholar
• Rednic S, Damian L, and Talarico R, et al. Relapsing polychondritis: state of the art on clinical practice guidelines. RMD Open. 2018;4(Suppl 1):e000788.
   Google Scholar
• Yoo JH, Chodosh J, Dana R. Relapsing polychondritis: systemic and ocular manifestations, differential diagnosis, management, and prognosis. Semin Ophthalmol. 2011;26(4–5):261–269.
   PubMed Web of Science ®Google Scholar
• Puéchal X, Terrier B, Mouthon L, et al. Relapsing polychondritis. Joint Bone Spine. 2014;81(2):118–124.
   PubMed Web of Science ®Google Scholar
• Vitale A, Sota J, Rigante D, et al. Relapsing polychondritis: an update on pathogenesis, clinical features, diagnostic tools, and therapeutic perspectives. Curr Rheumatol Rep. 2016;18(1):1–12.
   PubMed Web of Science ®Google Scholar
• Kemta Lekpa F, Chevalier X. Refractory relapsing polychondritis: challenges and solutions. Open Access Rheumatol. 2018;10:1–11.
   PubMedGoogle Scholar
• Mark KA, Franks AG. Colchicine and indomethacin for the treatment of relapsing polychondritis. J Am Acad Dermatol. 2002;46(2):S22–S24.
   PubMed Web of Science ®Google Scholar
• Barranco VP, Minor DB, Soloman H. Treatment of relapsing polychondritis with dapsone. Arch Dermatol. 1976;112(9):1286–1288.
   PubMedGoogle Scholar
• Hoang-Xuan T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology. 1990;97(7):892–898.
   PubMed Web of Science ®Google Scholar
• Mathew SD, Battafarano DF, Morris MJ. Relapsing polychondritis in the department of defense population and review of the literature. Semin Arthritis Rheum. 2012;42(1):70–83.
   PubMed Web of Science ®Google Scholar
• Almackenzie M, Alharbi A, Alhassan S, et al. Successful treatment of central nervous system vasculitis associated with relapsing polychondritis with cyclophosphamide. Am J Med Sci. 2017;353(5):495–497.
   PubMed Web of Science ®Google Scholar
• Nakazato Y, Mizoguchi F, Kohsaka H, et al. A case of relapsing polychondritis initially presenting with bronchial chondritis. Mod Rheumatol. 2014;24(6):1019–1022.
   PubMed Web of Science ®Google Scholar
• Ruhlen JL, Huston KA, Wood WG. Relapsing polychondritis with glomerulonephritis. Improvement with prednisone and cyclophosphamide. JAMA. 1981 27;245(8):847–848.
   PubMed Web of Science ®Google Scholar
• VanDer Lubbe PA, Miltenburg AM, Breedveld FC. Anti-CD4 monoclonal antibody for relapsing polychondritis. Lancet. 1991;337(8753):1349. (London, England).
   Web of Science ®Google Scholar
• Choy EHS, Chikanza IC, Kingsley GH, et al. Chimaeric anti-CD4 monoclonal antibody for relapsing polychondritis. Lancet. 1991;338(8764):450. (London, England).
   PubMed Web of Science ®Google Scholar
• Kemta Lekpa F, Kraus VB, Chevalier X. Biologics in relapsing polychondritis: a literature review. Semin Arthritis Rheum. 2012;41(5):712–719.
   PubMed Web of Science ®Google Scholar
• Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4):487–501.
   PubMed Web of Science ®Google Scholar
• Moulis G, Sailler L, Pugnet G, et al. Biologics in relapsing polychondritis: a case series. Clin Exp Rheumatol. 2013;31(6):937–939.
   PubMed Web of Science ®Google Scholar
• Moulis G, Pugnet G, Costedoat-Chalumeau N, et al. Efficacy and safety of biologics in relapsing polychondritis: a french national multicentre study. Ann Rheum Dis. 2018;77(8):1172–1178.
   PubMed Web of Science ®Google Scholar
• Biya J, Dury S, Perotin JM, et al. Assessment of TNF-α inhibitors in airway involvement of relapsing polychondritis: a systematic review. Medicine (Baltimore). 2019;98(44):e17768. (Baltimore).
   PubMed Web of Science ®Google Scholar
• Mpofu S, Estrach C, Curtis J, et al. Treatment of respiratory complications in recalcitrant relapsing polychondritis with infliximab. Rheumatology. 2003;42(9):1117–1118. (Oxford).
   PubMed Web of Science ®Google Scholar
• Saadoun D, Deslandre CJ, Allanore Y, et al. Sustained response to infliximab in 2 patients with refractory relapsing polychondritis. J Rheumatol. 2003;30(6):1394–1395.
   PubMed Web of Science ®Google Scholar
• Bell D, Wright D, Witt PD. Durability of nasal reconstruction in an adolescent with relapsing polychondritis treated with infliximab. Plast Reconstr Surg. 2007;120(4):1087–1088.
   PubMed Web of Science ®Google Scholar
• Marie I, Lahaxe L, Josse S, et al. Sustained response to infliximab in a patient with relapsing polychondritis with aortic involvement. Rheumatology. 2009;48(10):1328–1329. (Oxford).
   PubMed Web of Science ®Google Scholar
• Ratzinger G, Kuen-Spiegl M, Sepp N. Successful treatment of recalcitrant relapsing polychondritis with monoclonal antibodies. J Eur Acad Dermatol Venereol. 2009;23(4):474–475.
   PubMed Web of Science ®Google Scholar
• Richez C, Dumoulin C, Coutouly X, et al. Successful treatment of relapsing polychondritis with infliximab. Clin Exp Rheumatol. 2004;22(5):629–631.
   PubMed Web of Science ®Google Scholar
• Ghosn S, Malek J, Shbaklo Z, et al. Takayasu disease presenting as malignant pyoderma gangrenosum in a child with relapsing polychondritis. J Am Acad Dermatol. 2008;60(1):59.
   PubMedGoogle Scholar
• Nakamura NA, de Fb ST, Dos S MJQ, et al. Infliximab in relapsing polychondritis. Rev Bras Reumatol. 2010;50:214–216.
   Google Scholar
• Cazabon S, Over K, Butcher J. The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye. 2005;19(2):222–224. (Lond).
   PubMed Web of Science ®Google Scholar
• Jabbarvand M, Fard MA. Infliximab in a patient with refractory necrotizing scleritis associated with relapsing polychondritis. Ocul Immunol Inflamm. 2010;18(3):216–217.
   PubMed Web of Science ®Google Scholar
• Matzkies FG, Manger B, Schmitt-Haendle M, et al. Severe septicaemia in a patient with polychondritis and sweet’s syndrome after initiation of treatment with infliximab. Ann Rheum Dis. 2003;62(1):81–82.
   PubMed Web of Science ®Google Scholar
• Kondo T, Fukuta M, Takemoto A, et al. Limbic encephalitis associated with relapsing polychondritis responded to infliximab and maintained its condition without recurrence after discontinuation: a case report and review of the literature. Nagoya J Med Sci. 2014;76(3–4):361–368.
   PubMed Web of Science ®Google Scholar
• Subrahmanyam P, Balakrishnan C, Dasgupta B. Sustained response to etanercept after failing infliximab, in a patient with relapsing polychondritis with tracheomalacia. Scand J Rheumatol. 2008;37(3):239–240.
   PubMed Web of Science ®Google Scholar
• Carter JD. Treatment of relapsing polychondritis with a TNF antagonist. J Rheumatol. 2005;32(7):1413.
   PubMed Web of Science ®Google Scholar
• Pamuk ÖN, Harmandar F, Çakir N. The development of trigeminal neuralgia related to auricular chondritis in a patient with rheumatoid arthritis-relapsing polychondritis and its treatment with etanercept. Description of the first case. Clin Exp Rheumatol. 2009;27(1):128–129.
   PubMed Web of Science ®Google Scholar
• Schräder C, Lohmann J. Erfolgreiche Therapie mit Etanercept bei rezidivierender Polychondritis [Successful therapy with etanercept in relapsing polychondritis]. Z Rheumatol. 2010;69(4):356–358.
   PubMedGoogle Scholar
• Stael R, Smith V, Wittoek R, et al. Sustained response to tocilizumab in a patient with relapsing polychondritis with aortic involvement: a case based review. Clin Rheumatol. 2015;34(1):189–193.
   PubMed Web of Science ®Google Scholar
• Seymour MW, Home DM, Williams RO, et al. Prolonged response to anti-tumour necrosis factor treatment with adalimumab (humira) in relapsing polychondritis complicated by aortitis. Rheumatology. 2007;46(11):1738–1739. (Oxford).
   PubMed Web of Science ®Google Scholar
• Lahmer T, Knopf A, Treiber M, et al. Treatment of relapsing polychondritis with the TNF-alpha antagonist adalimumab. Clin Rheumatol. 2010;29(11):1331–1334.
   PubMed Web of Science ®Google Scholar
• Adamson R, Yazici Y, Katz ES, et al. Fatal acute necrotizing eosinophilic myocarditis temporally related to use of adalimumab in a patient with relapsing polychondritis. J Clin Rheumatol. 2013;19(7):386–389.
   PubMed Web of Science ®Google Scholar
• Moore GH, Rootman DB, Nathaniel Roybal V, et al. Orbital relapsing polychondritis: a unique presentation, complication, and treatment. Ophthalmic Plast Reconstr Surg. 2016;32(2):e34–e36.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77(17):1865–1879.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328.
   PubMed Web of Science ®Google Scholar
• Kawai M, Hagihara K, Hirano T, et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology. 2009;48(3):318–319. (Oxford).
   PubMed Web of Science ®Google Scholar
• Wendling D, Godfrin-Valnet M, Prati C. Treatment of relapsing polychondritis with tocilizumab. J Rheumatol. 2013;40(7):1232.
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Stone JH. Refractory relapsing polychondritis treated with serial success with interleukin 6 receptor blockade. J Rheumatol. 2013;40(1):100–101.
   PubMed Web of Science ®Google Scholar
• Farhat R, Clavel G, Villeneuve D, et al. Sustained remission with tocilizumab in refractory relapsing polychondritis with ocular involvement: a case series. Ocul Immunol Inflamm. 2021;29(1):1–5.
   PubMed Web of Science ®Google Scholar
• Weber E, Gaultier JB, and Paul S, et al. Réponse prolongée après traitement par tocilizumab d’une polychondrite atrophiante [sustained response with tocilizumab in a case of refractory relapsing polychondritis]. Rev Med Interne. 2014;35(3):196–198.
   PubMedGoogle Scholar
• Elourimi G, Soussan M, Warzocha U, et al. Efficacy of tocilizumab highlighted by FDG-PET/CT in a patient with relapsing polychondritis-associated aortitis. Rheumatol Int. 2017;37(11):1931–1935.
   PubMed Web of Science ®Google Scholar
• Tomelleri A, Campochiaro C, Sartorelli S, et al. Large-vessel vasculitis affecting the aorta and its branches in relapsing polychondritis: case series and systematic review of the literature. J Rheumatol. 2020;47(12):1780–1784.
   PubMed Web of Science ®Google Scholar
• Narshi CB, Allard SA. Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-α failure in a patient with relapsing polychondritis complicated by aortitis. Rheumatology. 2012;51(5):952–953. (Oxford).
   PubMed Web of Science ®Google Scholar
• Plunkett M, Lamont D, Brooker J, et al. Relapsing polychondritis: response to tocilizumab and association with colitis. J Clin Rheumatol. 2013;19(7):415–417.
   PubMed Web of Science ®Google Scholar
• Hanioka Y, Shimizu K, Yamagami K, et al. Exacerbation of ulcerative colitis with tocilizumab: a report of two cases, one with takayasu arteritis and the other with relapsing polychondritis. Intern Med. 2021;60(10):1615–1620.
   PubMed Web of Science ®Google Scholar
• Jin X, Zimmers TA, Zhang Z, et al. Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice. Gut. 2010;59(2):186–196.
   PubMed Web of Science ®Google Scholar
• Xie F, Yun H, Bernatsky S, et al. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612–2617. (Hoboken, NJ).
   PubMed Web of Science ®Google Scholar
• Pombo-Suarez M, Gomez-Reino JJ. Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15(4):319–326.
   PubMed Web of Science ®Google Scholar
• Iannone F, Lapadula G. The inhibitor of costimulation of T cells: abatacept. J Rheumatol Suppl. 2012;89:100–102.
   PubMedGoogle Scholar
• Peng SL, Rodriguez D. Abatacept in relapsing polychondritis. Ann Rheum Dis. 2013;72(8):1427–1429.
   PubMed Web of Science ®Google Scholar
• Moulis G, Sailler L, Astudillo L, et al. Abatacept for relapsing polychondritis. Rheumatology. 2010;49(5):1019. (Oxford).
   PubMed Web of Science ®Google Scholar
• Moulis G, Pugnet G, Sailler L, et al. Abatacept in relapsing polychondritis. Ann Rheum Dis. 2013;72(1):72.
   PubMedGoogle Scholar
• Leroux G, Costedoat-Chalumeau N, Brihaye B, et al. Treatment of relapsing polychondritis with rituximab: a retrospective study of nine patients. Arthritis Rheum. 2009;61(5):577–582.
   PubMed Web of Science ®Google Scholar
• McCarthy EM, Cunnane G. Treatment of relapsing polychondritis in the era of biological agents. Rheumatol Int. 2010;30(6):827–828.
   PubMed Web of Science ®Google Scholar
• Castrejón I, Ibáñez M, Vicente E, et al. Policondritis recidivante asociada a linfoma linfoplasmocítico y eritema nudoso [Relapsing polychondritis associated with a lymphoplasmocytic lymphoma and erythema nodosum]. Reumatol Clin. 2007;3(1):45–47.
   PubMedGoogle Scholar
• Abdwani R, Kolethekkat AA, Al Abri R. Refractory relapsing polychondritis in a child treated with antiCD20 monoclonal antibody (rituximab): first case report. Int J Pediatr Otorhinolaryngol. 2012;76(7):1061–1064.
   PubMed Web of Science ®Google Scholar
• Bakker AC, Joosten LAB, Arntz OJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum. 1997;40(5):893–900.
   PubMed Web of Science ®Google Scholar
• Vounotrypidis P, Sakellariou GT, Zisopoulos D, et al. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology. 2006;45(4):491–492. (Oxford).
   PubMed Web of Science ®Google Scholar
• Wendling D, Govindaraju S, Prati C, et al. Efficacy of anakinra in a patient with refractory relapsing polychondritis. Jt Bone Spine. 2008;75(5):622–624.
   PubMed Web of Science ®Google Scholar
• Buonuomo PS, Bracaglia C, Campana A, et al. Relapsing polychondritis: new therapeutic strategies with biological agents. Rheumatol Int. 2010;30(5):691–693.
   PubMed Web of Science ®Google Scholar
• Kontzias A, Kotlyar A, Laurence A, et al. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12(4):464–470.
   PubMed Web of Science ®Google Scholar
• Choy EH. Clinical significance of janus kinase inhibitor selectivity. Rheumatology. 2019;58(6):953–962. (Oxford).
   PubMed Web of Science ®Google Scholar
• Meshkov AD, Novikov PI, and Zhilyaev EV, et al. Tofacitinib in steroid-dependent relapsing polychondritis. Ann Rheum Dis. 2019;78(7) :e72.
   PubMed Web of Science ®Google Scholar
• Zheutlin A, Schiopu E. Relapsing polychondritis following treatment with secukinumab for ankylosing spondylitis: case report and review of the literature. Case Rep Rheumatol. 2018;2018:6760806.
   PubMedGoogle Scholar
• Dubey S, Gelder C, Pink G, et al. Respiratory subtype of relapsing polychondritis frequently presents as difficult asthma: a descriptive study of respiratory involvement in relapsing polychondritis with 13 patients from a single UK centre. ERJ Open Res. 2021;7(1):00170–2020.
   PubMedGoogle Scholar